Hengrui Medicine (600276.SH): Zemetafentanyl tablets obtained drug registration approval.

Zhijing Finance and Economics APP News, Hengrui Medicine (600276.SH) announced that recently, the company received a notification from the National Medical Products Administration (referred to as the "National Medical Products Administration"), conditionally approving the company's independently developed innovative drug SHR2554 tablets (Zemiva Sita tablets) for listing, used in adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously received at least first-line systemic treatment. Zemiva Sita tablets is the first independently developed EZH2 inhibitor in China.